414 related articles for article (PubMed ID: 37011953)
1. Maturation and abundance of tertiary lymphoid structures are associated with the efficacy of neoadjuvant chemoimmunotherapy in resectable non-small cell lung cancer.
Sun X; Liu W; Sun L; Mo H; Feng Y; Wu X; Li C; Chen C; Li J; Xin Y; Zhang Z; Wang C; Zhang B; Yue D
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 37011953
[TBL] [Abstract][Full Text] [Related]
2. Complete pathological remission and tertiary lymphoid structures are associated with the efficacy of resectable NSCLC receiving neoadjuvant chemoimmunotherapy: A double-center retrospective study.
Liu Y; Xiong L; Chen Y; Cai R; Xu X; Wang T; Guo Y; Ruan L; Fang Y; Zhang Q; Shen B; Ye J; Zhou G
Hum Vaccin Immunother; 2023 Dec; 19(3):2285902. PubMed ID: 38010104
[TBL] [Abstract][Full Text] [Related]
3. Combined inflammatory parameters and tertiary lymphoid structure predict prognosis in patients with resectable non-small cell lung cancer treated with neoadjuvant chemoimmunotherapy.
Xu F; Zhu H; Dong Y; Li L; Liu N; Yuan S
Front Immunol; 2023; 14():1244256. PubMed ID: 38155965
[TBL] [Abstract][Full Text] [Related]
4. Tertiary lymphoid structures combined with biomarkers of inflammation are associated with the efficacy of neoadjuvant immunochemotherapy in resectable non-small cell lung cancer: A retrospective study.
Xu F; Zhu H; Xiong D; Wang K; Dong Y; Li L; Yuan S
Thorac Cancer; 2024 Jan; 15(2):172-181. PubMed ID: 38057283
[TBL] [Abstract][Full Text] [Related]
5. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
[TBL] [Abstract][Full Text] [Related]
6. Tumor immune microenvironment predicts the pathologic response of neoadjuvant chemoimmunotherapy in non-small-cell lung cancer.
Han R; Zhang Y; Wang T; Xiao H; Luo Z; Shen C; Li J; Zhao C; Li L; Zhu M; Du H; Tang H; Ma Z; Wang Y; He Y
Cancer Sci; 2023 Jun; 114(6):2569-2583. PubMed ID: 36880750
[TBL] [Abstract][Full Text] [Related]
7. Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC.
Rocha P; Zhang J; Laza-Briviesca R; Cruz-Bermúdez A; Bota-Rabassedas N; Sanchez-Espiridon B; Yoshimura K; Behrens C; Lu W; Tang X; Pataer A; Parra ER; Haymaker C; Fujimoto J; Swisher SG; Heymach JV; Gibbons DL; Lee JJ; Sepesi B; Cascone T; Solis LM; Provencio M; Wistuba II; Kadara H
Clin Cancer Res; 2022 Jun; 28(11):2461-2473. PubMed ID: 35394499
[TBL] [Abstract][Full Text] [Related]
8. Efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy in potentially resectable stage IIIA/IIIB non-small cell lung cancer: Neo-Pre-IC, a single-arm phase 2 trial.
Sun C; Wang X; Xu Y; Shao G; Chen X; Liu Y; Zhang P; Lin X; Ma X; Qiu S; He H; Yang Z; Ma K
EClinicalMedicine; 2024 Feb; 68():102422. PubMed ID: 38304743
[TBL] [Abstract][Full Text] [Related]
9. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract][Full Text] [Related]
10. The predictive value of inflammatory biomarkers for major pathological response in non-small cell lung cancer patients receiving neoadjuvant chemoimmunotherapy and its association with the immune-related tumor microenvironment: a multi-center study.
Li C; Wu J; Jiang L; Zhang L; Huang J; Tian Y; Zhao Y; Liu X; Xia L; E H; Gao P; Hou L; Yang M; Ma M; Su C; Zhang H; Chen H; She Y; Xie D; Luo Q; Chen C
Cancer Immunol Immunother; 2023 Mar; 72(3):783-794. PubMed ID: 36056951
[TBL] [Abstract][Full Text] [Related]
11. A real-world comparison between neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable non-small cell lung cancer.
Zhang B; Xiao H; Pu X; Zhou C; Yang D; Li X; Wang W; Xiao Q
Cancer Med; 2023 Jan; 12(1):274-286. PubMed ID: 35621048
[TBL] [Abstract][Full Text] [Related]
12. The predictive role of hematologic markers in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy: a retrospective cohort study.
Liu W; Ren S; Yang L; Xiao Y; Zeng C; Chen C; Wu F; Hu Y
Int J Surg; 2023 Nov; 109(11):3519-3526. PubMed ID: 37578441
[TBL] [Abstract][Full Text] [Related]
13. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy.
Casarrubios M; Provencio M; Nadal E; Insa A; Del Rosario García-Campelo M; Lázaro-Quintela M; Dómine M; Majem M; Rodriguez-Abreu D; Martinez-Marti A; De Castro Carpeño J; Cobo M; López Vivanco G; Del Barco E; Bernabé R; Viñolas N; Barneto Aranda I; Massuti B; Sierra-Rodero B; Martinez-Toledo C; Fernández-Miranda I; Serna-Blanco R; Romero A; Calvo V; Cruz-Bermúdez A
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36171009
[TBL] [Abstract][Full Text] [Related]
14. Comparison of neoadjuvant chemoimmunotherapy and chemotherapy alone for resectable stage III non-small cell lung cancer: a real-world cohort study.
Zhou S; Liu Y; Liu K; Zhang J; Liang H; Wu Y; Ye H; Liang Y; Zhang J; Huang W
Front Immunol; 2023; 14():1343504. PubMed ID: 38187385
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II-III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial.
Zhu X; Sun L; Song N; He W; Xie B; Hu J; Zhang J; Yang J; Dai J; Bian D; Xia H; Sun F; Xiong A; Luo J; Zhang L; Yu H; Liu M; Liu H; Wang H; Zhang H; Chen C; Wu C; Duan L; Zhu Y; Zhang P; Jiang G
BMC Med; 2022 Dec; 20(1):493. PubMed ID: 36581917
[TBL] [Abstract][Full Text] [Related]
16. Utility of
Zhuang F; Haoran E; Huang J; Wu J; Xu L; Zhang L; Li Q; Li C; Zhao Y; Yang M; Ma M; She Y; Chen H; Luo Q; Zhao D; Chen C
Lung Cancer; 2023 Apr; 178():20-27. PubMed ID: 36764154
[TBL] [Abstract][Full Text] [Related]
17. Deep learning for predicting major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer: A multicentre study.
She Y; He B; Wang F; Zhong Y; Wang T; Liu Z; Yang M; Yu B; Deng J; Sun X; Wu C; Hou L; Zhu Y; Yang Y; Hu H; Dong D; Chen C; Tian J
EBioMedicine; 2022 Dec; 86():104364. PubMed ID: 36395737
[TBL] [Abstract][Full Text] [Related]
18. Pathological Response and Tumor Immune Microenvironment Remodeling Upon Neoadjuvant ALK-TKI Treatment in ALK-Rearranged Non-Small Cell Lung Cancer.
Zheng N; Zhang Y; Zeng Y; Ma Q; Zhang R; Zhao Q; Lu C; Tian J; Wang Z; Tang H; Luo N; Xiao H; He Y; Wu F; Li L
Target Oncol; 2023 Jul; 18(4):625-636. PubMed ID: 37351800
[TBL] [Abstract][Full Text] [Related]
19. [Application of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC].
Wang H; Han Y
Zhongguo Fei Ai Za Zhi; 2023 Nov; 26(11):822-832. PubMed ID: 38061884
[TBL] [Abstract][Full Text] [Related]
20. Germinal Centers Determine the Prognostic Relevance of Tertiary Lymphoid Structures and Are Impaired by Corticosteroids in Lung Squamous Cell Carcinoma.
Siliņa K; Soltermann A; Attar FM; Casanova R; Uckeley ZM; Thut H; Wandres M; Isajevs S; Cheng P; Curioni-Fontecedro A; Foukas P; Levesque MP; Moch H; Linē A; van den Broek M
Cancer Res; 2018 Mar; 78(5):1308-1320. PubMed ID: 29279354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
